ClinicalTrials.gg
CompletedNCT05763875V-MonoUpdated Oct 16, 2025Results posted

Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

A Phase 3 interventional study of Inclisiran and Ezetimibe in Hypercholesterolemia, sponsored by Novartis Pharmaceuticals. Completed at 42 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing inclisiran in Hypercholesterolemia — 6 open to participants now, 10 under way, 5 of them phase 3. inclisiran · Hypercholesterolemia.

Enrollment
13th of 24
350 · median 375
Started
2023
with 3 others
Phase 3
13 of 24
2 open now
Registered
14th of 24
by date
Lead sponsor
16 of 24
Novartis Pharmaceuticals

Among the 24 studies testing inclisiran in Hypercholesterolemia, this one is the 13th largest by enrollment, is one of 4 that started in 2023, is one of 13 in phase 3, and was the 14th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

6 of the 24 studies testing inclisiran in Hypercholesterolemia are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About inclisiran

inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing inclisiran in Hypercholesterolemia, or all of them as a file.
02

Study summary

CKJX839D12304 was a research study to determine if the study treatment, called inclisiran, in comparison to placebo and ezetimibe effectively reduces Low-Density Lipoprotein Cholesterol (LDL-C) as measured by percentage change from baseline to Day 150. This study was conducted in eligible participants with primary hypercholesterolemia not receiving any lipid-lowering therapy (LLT), with a 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk of less than 7.5%.

Read the detailed description

This study was a randomized, double-blind, placebo- and active comparator-controlled, multicenter study in 350 adult participants with primary hypercholesterolemia not receiving any LLT with a 10-year ASCVD risk score of less than 7.5%. This study evaluated the efficacy and safety of inclisiran sodium 300 mg, administered as a monotherapy in comparison to ezetimibe and placebo.

The study consisted of:

  • a screening period of up to 14 days;
  • a double-blind treatment period of 150+/- 5 days during which participants were randomly assigned to either the inclisiran arm, the ezetimibe arm or the placebo arm in a 2:1:1 ratio; and
  • a safety follow-up / End of Study visit conducted 30+5 days after the Day 150 visit.

The overall study duration was approximately 190 days.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • inclisiran
  • ezetimibe
  • LDL-C
  • monotherapy
  • primary hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria at screening:

  • signed prior to participation in study
  • fasting LDL-C of >= 100 mg/dL but \< 190 mg/dL
  • fasting triglycerides \<= 400 mg/dL
  • 10-year ASCVD risk score \< 7.5%
  • not on any lipid-lowering therapy within 90 days of screening

Key Exclusion Criteria:

  • history of ASCVD
  • diabetes mellitus or fasting plasma glucose of >= 7.0 mmol/L or >= 6.5%
  • secondary hypercholesterolemia, e.g. hypothyroidism (TSH above )
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
350 participants (actual)

Study arms

  • Experimental
    Inclisiran

    Inclisiran s.c and Placebo p.o

    Drug: Inclisiran · Drug: Matching Placebo for Ezetimibe

  • Active comparator
    Ezetimibe

    Placebo s.c. and Ezetimibe p.o.

    Drug: Ezetimibe · Drug: Matching Placebo for Inclisiran

  • Placebo comparator
    Placebo

    Placebo s.c. and Placebo p.o.

    Drug: Matching Placebo for Inclisiran · Drug: Matching Placebo for Ezetimibe

Interventions

  • 284 mg (equivalent to 300 mg inclisiran sodium) subcutaneous injection given on Day 1 and Day 90

    Also known as: KJX839

  • 10 mg over-encapsulated tablet taken once a day from Day 1 through Day 149

    Also known as: Sandoz ezetimibe

  • DrugMatching Placebo for Inclisiran

    0mg placebo injection solution for subcutaneous injection on Day 1 and Day 90

    Also known as: Placebo s.c.

  • DrugMatching Placebo for Ezetimibe

    0mg over-encapsulated placebo tablet taken once a day from Day 1 through Day 149

    Also known as: Placebo p.o.

06

What researchers measure

Primary outcomes

  1. Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150

    Percentage change in LDL-C from Baseline (day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.

    Time frame: Baseline, Day 150

Secondary outcomes

  1. Absolute Change in LDL-C From Baseline to Day 150

    Absolute change in LDL-C from Baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.

    Time frame: Baseline, Day 150

  2. Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 150

    Percentage change in PCSK9 from Baseline (Day 1) to Day 150 , Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.

    Time frame: Baseline, Day 150

  3. Percentage Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Day 150

    Percentage change in non-HDL-C from Baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.

    Time frame: Baseline, Day 150

  4. Percentage Change in Total Cholesterol (TC)/HDL-C Ratio From Baseline to Day 150

    Percentage change in total cholesterol/HDL-C ratio from Baseline (Day1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strate

    Time frame: Baseline, Day 150

  5. Percentage Change in Apolipoprotein B (Apo B) From Baseline to Day 150

    Percentage change in Apo B from Baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.

    Time frame: Baseline, Day 150

  6. Percentage Change in Apo B/Apo A-1 Ratio From Baseline to Day 150

    Percentage change in Apo B/Apo A-1 ratio from baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.

    Time frame: Baseline, Day 150

  7. Change in Lipoprotein (a) [Lp(a)] From Baseline to Day 150

    Day 150 / Baseline ratio in Lp(a) in Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.

    Time frame: Baseline, Day 150

  8. Incidence of Treatment Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)

    Incidence of TEAEs (regardless of seriousness) and SAEs by treatment group, including changes in laboratory results qualifying and reported as AEs.

    Time frame: From first dose of study treatment on Day 1 up to Day 180

07

Results

Posted Aug 13, 2025

Participant flow

Participants were enrolled at 42 investigative sites in 5 countries

Participant flow — Overall Study
MilestoneInclisiranEzetimibePlacebo
Started1748987
Completed1648684
Not completed1033
Withdrew: Subject decision521
Withdrew: Lost to follow-up412
Withdrew: Adverse event100

Outcome measures

PrimaryPercentage Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150

Percentage change in LDL-C from Baseline (day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · Percentage change from baseline
Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150
Percentage change from baselineInclisiranEzetimibePlacebo
LS Mean (Treatment Policy estimand)-46.54 (-50.20 to -42.88)-11.17 (-15.34 to -7.00)1.37 (-3.07 to 5.80)
LS Mean (Monotherapy estimand)-49.37 (-52.76 to -45.97)-11.92 (-15.87 to -7.98)-1.53 (-2.97 to 6.03)
Statistical analysis
  • Inclisiran vs Ezetimibe · ANCOVA · p = <0.0001 · Ls mean difference: -35.37 · 95% CI -40.88 to -29.86
  • Inclisiran vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: -47.91 · 95% CI -53.62 to -42.20
  • Inclisiran vs Ezetimibe · ANCOVA · p = <0.0001 · Ls mean difference: -37.44 · 95% CI -42.63 to -32.26
  • Inclisiran vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: -50.90 · 95% CI -56.51 to -45.28
SecondaryAbsolute Change in LDL-C From Baseline to Day 150

Absolute change in LDL-C from Baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · mg/dL
Absolute Change in LDL-C From Baseline to Day 150
mg/dLInclisiranEzetimibePlacebo
LS Mean (Treatment Policy estimand)-64.86 (-69.27 to -60.46)-17.55 (-22.53 to -12.57)-1.29 (-6.40 to 3.82)
LS Mean (Monotherapy estimand)-68.57 (-72.59 to -64.56)-18.52 (-23.16 to -13.89)-1.07 (-6.32 to 4.19)
Statistical analysis
  • Inclisiran vs Ezetimibe · ANCOVA · p = <0.0001 · Ls mean difference: -47.37 · 95% CI -53.91 to -40.72
  • Inclisiran vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: -63.57 · 95% CI -70.28 to -56.87
  • Inclisiran vs Ezetimibe · ANCOVA · p = <0.0001 · Ls mean difference: -50.05 · 95% CI -56.16 to -43.94
  • Inclisiran vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: -67.51 · 95% CI -74.09 to -60.92
SecondaryPercentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 150

Percentage change in PCSK9 from Baseline (Day 1) to Day 150 , Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · Percentage change from baseline
Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 150
Percentage change from baselineInclisiranEzetimibePlacebo
LS Mean (Treatment Policy estimand)-67.12 (-73.21 to -61.03)6.04 (-0.10 to 12.18)7.82 (0.35 to 15.29)
LS Mean (Monotherapy estimand)-71.31 (-76.73 to -65.89)5.56 (-0.67 to 11.79)8.16 (0.59 to 15.74)
Statistical analysis
  • Inclisiran vs Ezetimibe · ANCOVA · p = <0.0001 · Ls mean difference: -73.16 · 95% CI -81.76 to -64.56
  • Inclisiran vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: -74.94 · 95% CI -84.51 to -65.37
  • Inclisiran vs Ezetimibe · ANCOVA · p = <0.0001 · Ls mean difference: -76.87 · 95% CI -85.12 to -68.62
  • Inclisiran vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: -79.47 · 95% CI -88.77 to -70.17
SecondaryPercentage Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Day 150

Percentage change in non-HDL-C from Baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · Percentage change from baseline
Percentage Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Day 150
Percentage change from baselineInclisiranEzetimibePlacebo
LS Mean (Treatment Policy estimand)-40.45 (-43.50 to -37.40)-9.97 (-13.34 to -6.61)1.88 (-2.75 to 6.50)
LS Mean (Monotherapy estimand)-42.82 (-45.62 to -40.02)-10.84 (-13.84 to -7.84)2.04 (-2.63 to 6.71)
Statistical analysis
  • Inclisiran vs Ezetimibe · ANCOVA · p = <0.0001 · Ls mean difference: -30.48 · 95% CI -34.98 to -25.98
  • Inclisiran vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: -42.32 · 95% CI -47.83 to -36.82
  • Inclisiran vs Ezetimibe · ANCOVA · p = <0.0001 · Ls mean difference: -31.98 · 95% CI -36.07 to -27.89
  • Inclisiran vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: -44.86 · 95% CI -50.28 to -39.44
SecondaryPercentage Change in Total Cholesterol (TC)/HDL-C Ratio From Baseline to Day 150

Percentage change in total cholesterol/HDL-C ratio from Baseline (Day1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strate

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · Percentage change from baseline
Percentage Change in Total Cholesterol (TC)/HDL-C Ratio From Baseline to Day 150
Percentage change from baselineInclisiranEzetimibePlacebo
LS Mean (Treatment Policy estimand)-31.54 (-35.43 to -27.65)-6.70 (-10.61 to -2.78)2.31 (-4.05 to 8.68)
LS Mean (Monotherapy estimand)-33.56 (-37.32 to -29.79)-6.98 (-10.99 to -2.97)2.51 (-3.90 to 8.91)
Statistical analysis
  • Inclisiran vs Ezetimibe · ANCOVA · p = <0.0001 · Ls mean difference: -24.84 · 95% CI -30.32 to -19.36
  • Inclisiran vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: -33.85 · 95% CI -41.27 to -26.44
  • Inclisiran vs Ezetimibe · ANCOVA · p = <0.0001 · Ls mean difference: -26.58 · 95% CI -32.07 to -21.09
  • Inclisiran vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: -36.06 · 95% CI -43.46 to -28.67
SecondaryPercentage Change in Apolipoprotein B (Apo B) From Baseline to Day 150

Percentage change in Apo B from Baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · Percentage change from baseline
Percentage Change in Apolipoprotein B (Apo B) From Baseline to Day 150
Percentage change from baselineInclisiranEzetimibePlacebo
LS Mean (Treatment Policy estimand)-37.39 (-40.25 to -34.54)-8.41 (-11.71 to -5.12)-0.73 (-4.18 to 2.72)
LS Mean (Monotherapy estimand)-39.36 (-42.00 to -36.72)-9.20 (-12.13 to -6.28)-0.58 (-4.07 to 2.90)
Statistical analysis
  • Inclisiran vs Ezetimibe · ANCOVA · p = <0.0001 · Ls mean difference: -28.98 · 95% CI -33.30 to -24.65
  • Inclisiran vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: -36.66 · 95% CI -41.10 to -32.22
  • Inclisiran vs Ezetimibe · ANCOVA · p = <0.0001 · Ls mean difference: -30.16 · 95% CI -34.08 to -26.23
  • Inclisiran vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: -38.78 · 95% CI -43.12 to -34.43
SecondaryPercentage Change in Apo B/Apo A-1 Ratio From Baseline to Day 150

Percentage change in Apo B/Apo A-1 ratio from baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · Percentage change from baseline
Percentage Change in Apo B/Apo A-1 Ratio From Baseline to Day 150
Percentage change from baselineInclisiranEzetimibePlacebo
LS Mean (Treatment Policy estimand)-37.79 (-43.03 to -32.55)-7.55 (-11.74 to -3.36)-2.65 (-5.69 to 0.39)
LS Mean (Monotherapy estimand)-40.03 (-45.25 to -34.82)-7.69 (-12.00 to -3.37)-2.65 (-5.81 to 0.50)
Statistical analysis
  • Inclisiran vs Ezetimibe · ANCOVA · p = <0.0001 · Ls mean difference: -30.24 · 95% CI -36.92 to -23.57
  • Inclisiran vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: -35.15 · 95% CI -41.18 to -29.12
  • Inclisiran vs Ezetimibe · ANCOVA · p = <0.0001 · Ls mean difference: -32.34 · 95% CI -39.10 to -25.59
  • Inclisiran vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: -37.38 · 95% CI -43.44 to -31.31
SecondaryChange in Lipoprotein (a) [Lp(a)] From Baseline to Day 150

Day 150 / Baseline ratio in Lp(a) in Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.

Time frame:
Baseline, Day 150
Reported as:
Geometric least squares mean · Ratio from baseline
Change in Lipoprotein (a) [Lp(a)] From Baseline to Day 150
Ratio from baselineInclisiranEzetimibePlacebo
LS Mean (Treatment Policy estimand)0.690 (0.611 to 0.780)0.911 (0.830 to 1.000)0.923 (0.803 to 1.060)
LS Mean (Monotherapy estimand)0.687 (0.612 to 0.722)0.912 (0.836 to 0.95)0.922 (0.800 to 1.062)
Statistical analysis
  • Inclisiran vs Ezetimibe · ANCOVA · p = 0.0002 · Ratio of geometric mean: 0.757 · 95% CI 0.650 to 0.882
  • Inclisiran vs Placebo · ANCOVA · p = 0.0010 · Ratio of geometric mean: 0.748 · 95% CI 0.622 to 0.898
  • Inclisiran vs Ezetimibe · ANCOVA · p = <0.0001 · Ratio of geometric mean: 0.753 · 95% CI 0.652 to 0.871
  • Inclisiran vs Placebo · ANCOVA · p = 0.0008 · Ratio of geometric mean: 0.746 · 95% CI 0.622 to 0.893
SecondaryIncidence of Treatment Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)

Incidence of TEAEs (regardless of seriousness) and SAEs by treatment group, including changes in laboratory results qualifying and reported as AEs.

Time frame:
From first dose of study treatment on Day 1 up to Day 180
Reported as:
Count of participants · Participants
Incidence of Treatment Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)
ParticipantsInclisiranEzetimibePlacebo
AEs542725
AEs related to s.c. treatment (Inclisiran or s.c. matching placebo)1140
AEs related to p.o. treatment (ezetimibe or p.o. matching placebo)322
SAEs100
SAEs related to s.c. treatment (Inclisiran or s.c. matching placebo)000
SAEs related to p.o. treatment (ezetimibe or p.o. matching placebo)000
Fatal SAEs000
AEs leading to treatment discontinuation of inclisiran or s.c. matching placebo300
AEs leading to treatment discontinuation of ezetimibe or p.o. matching placebo400

Adverse events

Collected over From first dose of study treatment on Day 1 up to Day 180. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inclisiran0/174 (0%)1/174 (0.6%)19/174 (10.9%)
Ezetimibe0/89 (0%)0/89 (0%)18/89 (20.2%)
Placebo0/87 (0%)0/87 (0%)13/87 (14.9%)
Total0/350 (0%)1/350 (0.3%)50/350 (14.3%)
Most frequent serious events
Most frequent serious events
EventInclisiranEzetimibePlaceboTotal
Femur fractureInjury, poisoning and procedural complications1/1740/890/871/350
Most frequent other events
Showing 10 of 12
Most frequent other events
EventInclisiranEzetimibePlaceboTotal
COVID-19Infections and infestations1/1742/893/876/350
NasopharyngitisInfections and infestations6/1743/893/8712/350
HeadacheNervous system disorders6/1740/890/876/350
DiarrhoeaGastrointestinal disorders2/1741/892/875/350
Urinary tract infectionInfections and infestations3/1742/892/877/350
HypertensionVascular disorders1/1741/892/874/350
VomitingGastrointestinal disorders2/1742/890/874/350
GastroenteritisInfections and infestations2/1742/890/874/350
Upper respiratory tract infectionInfections and infestations2/1742/891/875/350
FallInjury, poisoning and procedural complications0/1742/891/873/350

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)InclisiranEzetimibePlaceboTotal
<=18 years0000
Between 18 and 65 years1688683337
>=65 years63413
Age, Continuous
Age, Continuous(years)InclisiranEzetimibePlaceboTotal
Mean45.7 ± 11.7446.3 ± 10.9046.7 ± 11.5546.1 ± 11.46
Sex: Female, Male
Sex: Female, Male(Participants)InclisiranEzetimibePlaceboTotal
Female1045659219
Male703328131
Race (NIH/OMB)
Race (NIH/OMB)(Participants)InclisiranEzetimibePlaceboTotal
American Indian or Alaska Native1010929
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American2071037
White1407167278
More than one race4015
Unknown or Not Reported0000
Baseline Low-Density Lipoprotein Cholesterol (LDL-C)
Baseline Low-Density Lipoprotein Cholesterol (LDL-C)(mg/dL)InclisiranEzetimibePlaceboTotal
Mean135.8 ± 27.01134.4 ± 25.82135.4 ± 28.69135.4 ± 27.07
08

Study locations

42 sites
  • Parkway Medical Center
    Birmingham, Alabama 35215, United States
  • SEC Clinical Research
    Dothan, Alabama 36305, United States
  • Hillcrest Medical Research
    DeLand, Florida 32720, United States
  • ClinCloud
    Maitland, Florida 32751, United States
  • Alma Clinical Research Inc
    Miami, Florida 33165, United States
  • Inpatient Research Clinical LLC
    Miami Lakes, Florida 33014, United States
  • Harmony Clinical Research
    North Miami Beach, Florida 33162, United States
  • Fam Medical Specialists Of Fl Plc
    Plant City, Florida 33563, United States
  • Cozy Research LLC
    Zephyrhills, Florida 33541, United States
  • Koch Family Medicine
    Morton, Illinois 61550, United States
  • Grace Research LLC
    Bossier City, Louisiana 71111, United States
  • Grace Research Llc
    Shreveport, Louisiana 71101, United States
  • Southern Clin Research Clinic
    Zachary, Louisiana 70791, United States
  • Prime Global Research Inc
    The Bronx, New York 10456, United States
  • Monroe Biomedical Research
    Monroe, North Carolina 28112, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58103, United States
  • WellNow Urgent Care and Research
    Huber Heights, Ohio 45424, United States
  • Conrad Clinical Research
    Edmond, Oklahoma 73013, United States
  • Compass Point Research
    Nashville, Tennessee 37203, United States
  • Mt Olympus Medical Research
    Sugar Land, Texas 77479, United States
  • Dominion Medical Associates
    Richmond, Virginia 23219, United States
  • Spaulding Clinical Research
    West Bend, Wisconsin 53095, United States
  • Novartis Investigative Site
    Barranquilla, Atlántico 080012, Colombia
  • Novartis Investigative Site
    Floridablanca, Santander Department 57-7, Colombia
  • Novartis Investigative Site
    Manizales, 170008, Colombia
  • Novartis Investigative Site
    San Gil, 684031, Colombia
  • Novartis Investigative Site
    Munich, Bavaria 80809, Germany
  • Novartis Investigative Site
    Hanover, Lower Saxony 30449, Germany
  • Novartis Investigative Site
    Löhne, North Rhine-Westphalia 32584, Germany
  • Novartis Investigative Site
    Jerichow, Saxony-Anhalt 39319, Germany
  • Novartis Investigative Site
    Berlin, 10787, Germany
  • Novartis Investigative Site
    Bochum, 44789, Germany
  • Novartis Investigative Site
    Gladbeck, 45968, Germany
  • Novartis Investigative Site
    Hamburg, 22607, Germany
  • Novartis Investigative Site
    Papenburg, 26871, Germany
  • Novartis Investigative Site
    Budapest, 1083, Hungary
  • Novartis Investigative Site
    Pécs, 7623, Hungary
  • Novartis Investigative Site
    Monterrey, Nuevo León 64060, Mexico
  • Novartis Investigative Site
    Monterrey, Nuevo León 64440, Mexico
  • Novartis Investigative Site
    Mérida, Yucatán 97070, Mexico
  • Novartis Investigative Site
    Culiacan Sinaloa, 80230, Mexico
  • Novartis Investigative Site
    Querétaro, 76000, Mexico
09

References and documents

Publications

  • Taub PR, Gutierrez A, Wewers D, Garcia Cantu E, Cao H, Deck C, Lesogor A, Ott D, Mena-Madrazo J, Zang X, Wright RS. Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial. J Am Coll Cardiol. 2025 Jul 22;86(3):196-208. doi: 10.1016/j.jacc.2025.04.049. Epub 2025 May 5. PubMed 40392667 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Jun 2024, 15 months.

Results were first posted in Aug 2025, 1 year 1 month after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 15 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2023
First posted
Mar 10, 2023
StartActual
Mar 15, 2023
Primary completionActual
Jun 20, 2024
CompletionActual
Jun 20, 2024
Results first posted
Aug 13, 2025
Last update
Oct 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05763875
Responsible party
Sponsor
First posted
Mar 10, 2023
Start date
Mar 15, 2023
Primary completion
Jun 20, 2024
Completion
Jun 20, 2024
Results posted
Aug 13, 2025
Last update
Oct 16, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion